TORONTO, June 12, 2018 /PRNewswire/ --
Eyecarrot Innovations Corp ("Eyecarrot" or the "Company") (TSX-V: EYC) (OTCQB:EYCCF) is pleased to announce the appointment of Dr. Stefan Collier as an Advisor in Neurophotonics; a field of study focusing on the use of photons or quantum units of light to study the brain and its processes at the
(Logo: https://mma.prnewswire.com/media/688290/Eyecarrot_Logo.jpg )
"We are very excited to continue to expand the Eyecarrot team with the appointment of Dr. Collier. He has been recognized internationally for his contribution to the field of Functional Syntonic Optometry, speaks 7 languages, and will help the company in expanding the Binovi Platform globally, including Europe" commented Adam Cegielski, Eyecarrot CEO.
"I would like to commend the company on the recently released Binovi Touch Saccadic Fixator, the expansion of the Binovi Platform into Spain, and look forward to working with the Eyecarrot team" stated Dr. Stefan Collier, Eyecarrot Advisor.
About Dr. Stefan Collier, F.O., FCSO, CSO trustee, Dean BOAF
Dr. Stefan Collier is a leader in bringing functional optometry & Syntonics to Europe. He received from OEPF the Skeffington-Alexander International Award in 2010 and the Armand Bastien Award in 2002 and 2004. He received from (CSO) College of Syntonic Optometry the H. Riley Spitler Award in 2011. He received from (SOE) European Society of Optometrists the SOE Award in 2009.
Eyecarrot's BinoviTM platform is an innovative healthcare technology solution that integrates software, hardware, data and expert knowledge. Binovi helps Optometrists treat vision issues with in-office therapy as well as doctor led home based activities to better serve and increase the patient's experience and their therapy needs. The goal is to help transform vision performance for the 1 in 4 people worldwide that suffer from vision-related issues going beyond visual acuity. The company is transforming how vision healthcare services are integrated, while addressing key challenges in the health system.
On behalf of the Board of Directors Adam Cegielski President | CEO
Forward looking information
Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at http://www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Brian Stecyk, President & CEO CellCube Energy Storage Systems Inc. Telephone: +1-800-882-3213 Email: firstname.lastname@example.org
SOURCE Eyecarrot Innovations Corp
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All